Scott L Harbeson

This inventor holds 60 USPTO granted patents and 27 published patent applications, plus 7 CIPO patents and 19 EPO patents, primarily in Deuterated Compounds (CPC class C07D). Top assignees: Concert Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., Merrell Pharmaceuticals, Inc.. Active years: 1996-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott L Harbeson. Retrieved from https://idiyas.com/inventor/scott-l-harbeson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 60 (Patent Applications = 27)

% Patents Active = 70.0

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 19 (Patent Applications = 32)

Average Co-Inventor Count = 1.8

ph-index = 10

Forward Citations = 625(Granted Patents)

Forward Citations (Not Self Cited) = 562(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Cincinnati, OH (US) (1998 - 2001)
Lexington, MA (US) (2013)
Cambridge, MA (US) (1996 - 2020)

Company Filing History:

47 out of 136

Concert Pharmaceuticals, Inc.

patents

7 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

4 out of 194

Merrell Pharmaceuticals, Inc.

patents

4. 2 out of 834,513

Other

patents

Years Active: 1996-2020

Loading Chart...

Areas of Expertise:

Deuterated Compounds

Xanthine Derivatives

Enzyme Inhibitors

Triazolobenzodiazepines

Morpholine Derivatives

Thienotriazolodiazepines

Pyrazinoisoquinolines

Cilostazol Analogues

Benzimidazoles

Serine Protease Inhibitors

Pyrimidinecarboxamide Derivatives

Fluorinated Derivatives

60 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10683305 - Deuterated OTX-015 (2020-06-16),

2. 10385042 - Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase (2019-08-20),

3. 10357499 - Substituted triazolobenzodiazepines (2019-07-23),

4. 10335413 - Substituted xanthine derivatives (2019-07-02),

5. 10039769 - Substituted triazolobenzodiazepines (2018-08-07),

6. 9944635 - Deuterated pyrazino[2,1-a]isoquinoline compounds and methods of treatment using the same (2018-04-17),

7. 9918987 - Substituted xanthine derivatives (2018-03-20),

8. 9783528 - Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase (2017-10-10),

9. 9694017 - Substituted triazolobenzodiazepines (2017-07-04),

10. 9676790 - Substituted thienotriazolodiazapines (2017-06-13),

11. 9493463 - Substituted xanthine derivatives (2016-11-15),

12. 9492457 - Substituted xanthine derivatives (2016-11-15),

13. 9453009 - Synthesis of deuterated morpholine derivatives (2016-09-27),

14. 9328113 - Substituted xanthine derivatives (2016-05-03),

15. 9249149 - Deuterated derivatives of ruxolitinib (2016-02-02),

Title: The Innovative Mind of Scott L Harbeson

Introduction: Scott L Harbeson is a pioneering inventor based in Cambridge, MA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Scott L Harbeson holds several patents in various technological domains, showcasing his versatility and ingenuity in creating novel solutions to complex problems.

Career Highlights: With a career spanning over two decades, Scott L Harbeson has consistently pushed the boundaries of innovation, leading to the development of cutting-edge technologies that have revolutionized industries.

Collaborations: Throughout his career, Scott L Harbeson has collaborated with leading research institutions, universities, and tech companies, fostering a culture of innovation and knowledge sharing that has propelled his inventions to new heights.

Conclusion: Scott L Harbeson's relentless pursuit of innovation and his passion for creating transformative technologies have solidified his reputation as a visionary inventor in the vibrant tech hub of Cambridge, MA.

Profile summary based on public USPTO records.